Ante S. Lundberg

6.0k total citations · 2 hit papers
39 papers, 4.7k citations indexed

About

Ante S. Lundberg is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ante S. Lundberg has authored 39 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 14 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Ante S. Lundberg's work include Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Blood transfusion and management (4 papers). Ante S. Lundberg is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Blood transfusion and management (4 papers). Ante S. Lundberg collaborates with scholars based in United States, France and Italy. Ante S. Lundberg's co-authors include Robert A. Weinberg, William C. Hahn, Mary W. Brooks, Roderick L. Beijersbergen, Christopher M. Counter, Piyush B. Gupta, Sheila A. Stewart, Mark D. Fleming, James M. Roberts and Claude Sardet and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Ante S. Lundberg

39 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Creation of human tumour cells with defined genetic elements

1999 1.8k citations William C. Hahn, Christopher M. Counter et al. Nature profile →
Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

1998 881 citations Ante S. Lundberg, Robert A. Weinberg Molecular and Cellular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ante S. Lundberg United States	17	3.0k	1.7k	1.1k	558	545	39	4.7k
Masayoshi Namba Japan	35	2.8k 0.9×	1.1k 0.7×	630 0.6×	402 0.7×	533 1.0×	186	4.8k
David Wynford‐Thomas United Kingdom	46	3.6k 1.2×	2.6k 1.5×	1.9k 1.8×	389 0.7×	700 1.3×	158	7.0k
Ross A. Dickins Australia	27	3.3k 1.1×	1.5k 0.8×	966 0.9×	278 0.5×	805 1.5×	44	5.0k
Philip M. Reaper United Kingdom	16	4.2k 1.4×	2.0k 1.2×	1.7k 1.6×	391 0.7×	721 1.3×	19	5.4k
Cornelius Miething Germany	28	3.0k 1.0×	1.5k 0.9×	809 0.8×	219 0.4×	740 1.4×	68	5.1k
Steven P. Linke United States	26	3.5k 1.2×	2.2k 1.2×	461 0.4×	638 1.1×	965 1.8×	41	4.7k
Ann Zeuner Italy	35	2.4k 0.8×	1.4k 0.8×	581 0.5×	434 0.8×	867 1.6×	72	4.3k
Masaharu Akiyama Japan	32	3.2k 1.1×	1.3k 0.7×	1.1k 1.0×	145 0.3×	404 0.7×	90	5.1k
Asha S. Multani United States	40	5.0k 1.7×	3.3k 1.9×	1.4k 1.3×	677 1.2×	1.9k 3.4×	126	8.2k
Athanassios Kotsinas Greece	25	2.8k 0.9×	1.4k 0.8×	411 0.4×	431 0.8×	702 1.3×	70	3.9k

Countries citing papers authored by Ante S. Lundberg

Since Specialization

Citations

This map shows the geographic impact of Ante S. Lundberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ante S. Lundberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ante S. Lundberg more than expected).

Fields of papers citing papers by Ante S. Lundberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ante S. Lundberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ante S. Lundberg. The network helps show where Ante S. Lundberg may publish in the future.

Co-authorship network of co-authors of Ante S. Lundberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ante S. Lundberg. A scholar is included among the top collaborators of Ante S. Lundberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ante S. Lundberg. Ante S. Lundberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Antoniani, Chiara, Vasco Meneghini, Annalisa Lattanzi, et al.. (2018). Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood. 131(17). 1960–1973. 145 indexed citations

Fridkis‐Hareli, Masha, Michael Storek, Richard Altman, et al.. (2018). The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models. Molecular Immunology. 105. 150–164. 21 indexed citations

Risitano, Antonio M., Michael Storek, Mittie K. Doyle, et al.. (2015). Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients. Blood. 126(23). 2137–2137. 23 indexed citations

Stone, Richard M., Steven L. Allen, Arnaud Pigneux, et al.. (2011). A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE).. Journal of Clinical Oncology. 29(15_suppl). 6520–6520. 2 indexed citations

Allen, Steven L. & Ante S. Lundberg. (2011). Amonafide: a potential role in treating acute myeloid leukemia. Expert Opinion on Investigational Drugs. 20(7). 995–1003. 24 indexed citations

Yin, Wei, et al.. (2009). Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Biopharmaceutics & Drug Disposition. 31(1). 72–81. 5 indexed citations

Allen, Steven L., Jonathan E. Kolitz, Ante S. Lundberg, et al.. (2009). Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leukemia Research. 34(4). 487–491. 10 indexed citations

Erba, Harry P., Margaret O’Donnell, Steven L. Allen, et al.. (2009). Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.. Blood. 114(22). 1047–1047. 3 indexed citations

Rizzieri, David A., Harry P. Erba, M O’Donnell, et al.. (2008). Amonafide + ara-C in secondary acute myeloid leukemia (sAML): Consistent efficacy in poor risk populations. Journal of Clinical Oncology. 26(15_suppl). 7027–7027. 1 indexed citations

10.

Capizzi, Robert L., L Roman, S. Tjulandin, et al.. (2008). Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1055–1055. 25 indexed citations

11.

Erba, Harry P., David A. Rizzieri, Ante S. Lundberg, et al.. (2007). Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML). Journal of Clinical Oncology. 25(18_suppl). 7065–7065. 3 indexed citations

12.

Allen, Steven L., Jonathan E. Kolitz, Ante S. Lundberg, et al.. (2005). Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML). Journal of Clinical Oncology. 23(16_suppl). 6602–6602. 2 indexed citations

13.

Lundberg, Ante S., Scott H. Randell, Sheila A. Stewart, et al.. (2002). Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 21(29). 4577–4586. 190 indexed citations

14.

Schratt, Gerhard, Birgit Weinhold, Ante S. Lundberg, et al.. (2001). Serum Response Factor Is Required for Immediate-Early Gene Activation yet Is Dispensable for Proliferation of Embryonic Stem Cells. Molecular and Cellular Biology. 21(8). 2933–2943. 123 indexed citations

15.

Lundberg, Ante S., William C. Hahn, Piyush B. Gupta, & Robert A. Weinberg. (2000). Genes involved in senescence and immortalization. Current Opinion in Cell Biology. 12(6). 705–709. 248 indexed citations

16.

Hahn, William C., Christopher M. Counter, Ante S. Lundberg, et al.. (1999). Creation of human tumour cells with defined genetic elements. Nature. 400(6743). 464–468. 1810 indexed citations breakdown →

17.

Lundberg, Ante S. & Robert A. Weinberg. (1998). Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes. Molecular and Cellular Biology. 18(2). 753–761. 881 indexed citations breakdown →

18.

McDevitt, Hugh O., David C. Wraith, Dawn E. Smilek, Ante S. Lundberg, & Lawrence Steinman. (1989). Evolution, Function, and Utilization of Major Histocompatibility Complex Polymorphism in Autoimmune Disease. Cold Spring Harbor Symposia on Quantitative Biology. 54(0). 853–857. 6 indexed citations

19.

Zucker, Marjorie B., et al.. (1969). Recent advances in preparation of platelet concentrates from ACD and CPD blood. Cryobiology. 5(4). 288–288. 14 indexed citations

20.

Zucker, Marjorie B., James H. Pert, Ante S. Lundberg, Ronald A. Yankee, & E. S. Henderson. (1969). Preservation and Clinical Use of Platelets¹. Vox Sanguinis. 16(5). 373–381. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact